Indraprastha Medical Corporation Limited reported a net profit of ₹55.85 crore for the quarter ended June 30, 2026, reflecting an 8.5% year-on-year growth from ₹51.46 crore in Q1FY26. The healthcare provider’s revenue from operations rose by 11.3% to ₹406.15 crore, up from ₹365.06 crore in the corresponding period of the previous year, driven by increased patient volumes and higher professional charges to doctors.

The Board of Directors approved the unaudited financial results at its meeting held on August 6, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, S N Dhawan & Co LLP, in accordance with Standard on Review Engagements (SRE) 2410. The company also fixed September 18, 2026, as the record date for determining shareholders entitled to the dividend for the fiscal year 2025-26 and for the upcoming Annual General Meeting (AGM).

Financial Performance Highlights

Revenue from operations stood at ₹406.15 crore, compared to ₹365.06 crore in Q1FY26. Other income increased by 22.0% to ₹8.42 crore from ₹6.90 crore. Total income for the quarter reached ₹414.57 crore, up from ₹371.96 crore in the prior year period.

Total expenses rose by 11.9% to ₹339.75 crore from ₹303.65 crore. Professional charges to doctors, a key cost component for the hospital chain, increased by 13.7% to ₹111.15 crore from ₹97.84 crore. Employee benefits expense grew by 12.3% to ₹72.96 crore, while cost of materials consumed rose by 11.6% to ₹70.13 crore. Other expenses increased by 8.5% to ₹72.10 crore.

Profit before tax climbed 9.5% to ₹74.82 crore from ₹68.31 crore. Tax expense was recorded at ₹19.68 crore, comprising current tax of ₹19.68 crore and deferred tax credit of ₹0.71 crore. The net profit after tax improved to ₹55.85 crore from ₹51.46 crore. Basic and diluted earnings per share were ₹6.09, compared to ₹5.61 in Q1FY26.

Corporate Actions and Governance

The Board approved convening the thirty-eighth Annual General Meeting on September 24, 2026, via video conferencing or other audio-visual means. The record date for dividend entitlement and AGM participation is set for September 18, 2026.

Additionally, the Board re-appointed M/s Devarajan Swaminathan and Co., Cost Accountants, as Cost Auditors for the financial year 2026-27, based on the recommendation of the Audit Committee. The company operates in a single segment—Healthcare—and does not have any subsidiaries, associates, or joint ventures as of June 30, 2026.

What the Numbers Show

The 11.3% revenue growth outpaced the 8.5% rise in net profit, indicating margin compression pressure. While top-line expansion was robust, total expenses grew at a slightly faster rate of 11.9%, primarily driven by a 13.7% increase in professional charges to doctors. This suggests that while patient inflow and service utilization are rising, the cost structure is adjusting accordingly, impacting bottom-line leverage in this quarter.

Indraprastha Medical Corporation Limited has scheduled a series of one-on-one meetings with investors and analysts in Mumbai on June 4 and 5, 2026. The management intends to engage with representatives from various mutual funds and Portfolio Management Services (PMS) companies to discuss the company's performance and outlook. The initiative is undertaken pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

The meetings will facilitate direct engagement with key institutional investors, including HDFC Mutual Fund, AXIS Mutual Fund, PineBridge Investments, and Birla Mutual Fund. Other participants include Nippon Mutual Fund, SBI Mutual Fund, UTI Mutual Fund, InCred AMC, and Grow Mutual Fund. Additionally, the management will meet with PMS firms such as Kriis PMS, Alfaccurate PMS, and Emkay PMS.

The company clarified that the schedule is subject to change due to exigencies on the part of the investors or the company. Furthermore, Indraprastha Medical Corporation Limited stated that no unpublished price sensitive information pertaining to the company will be shared during the meet. The disclosure was filed by Priya Ranjan, AVP – Corporate Affairs & Legal and Company Secretary & Compliance Officer.

Investor Meet Schedule